Tirzepatide Peptide Pen (GIP/GLP-1 Agonist) | 60mg

Tirzepatide is a synthetic dual GIP and GLP-1 receptor agonist, supplied here pre-mixed at 60 mg in a 3 ml stabilised cartridge at a stated 20 mg/ml. No lyophilised powder and no reconstitution step.

Important: a licensed tirzepatide medicine exists in the UK

Unlike most compounds in this catalogue, tirzepatide is the active ingredient of a licensed prescription medicine available in the United Kingdom. That medicine is manufactured to pharmaceutical standards, dispensed against a prescription, and supported by a regulatory dossier and pharmacovigilance.

The material on this page is not that medicine and is not a substitute for it. It is an in-vitro research chemical supplied for laboratory use, it holds no marketing authorisation, and it is not supplied for administration to any person. Anyone seeking tirzepatide for a medical purpose should be speaking to a prescriber, not to a research chemical supplier. We will not supply this material to anyone indicating an intent to use it in a person.

What tirzepatide is

Tirzepatide is a 39-amino-acid synthetic peptide, C₂₂₅H₃₄₈N₄₈O₆₈, 4813 g/mol. Its backbone is derived from GIP — glucose-dependent insulinotropic polypeptide — rather than from GLP-1, which is a detail frequently reported the other way around. Engineered substitutions give it appreciable activity at the GLP-1 receptor as well, making it an unbalanced dual agonist: its potency at the two receptors is not equal, and the imbalance is a designed property rather than an artefact.

Two structural features carry the pharmacokinetics. A C20 fatty diacid is conjugated to the peptide, binding reversibly to serum albumin and extending circulating half-life to a weekly interval. And α-aminoisobutyric acid residues are substituted at positions vulnerable to dipeptidyl peptidase-4, blocking the cleavage that clears native incretins within minutes.

Tirz pen: the same thing under a shorter name

Most people searching for this product type “tirz” rather than the full compound name, and the two mean the same thing. A tirz is a pre-filled tirzepatide cartridge in a dial-dosing pen, as opposed to lyophilised powder in a vial.

This pen holds 60 mg in a sealed 3 ml cartridge, at 20 mg/ml. The dial is graduated at 12 clicks = 2.5 mg. Those are device figures — what the mechanism displaces, not what should be dispensed.

Applications in research

• Incretin receptor pharmacology. Comparative binding and functional assays at the GIP and GLP-1 receptors, where an unbalanced dual agonist is needed alongside selective agonists for each.
• Receptor bias and signalling. Work distinguishing G-protein-mediated signalling from β-arrestin recruitment, an area where tirzepatide's profile differs from that of GLP-1-selective agonists.
• Albumin-binding pharmacokinetics. Plasma protein binding and release-rate measurement, with the C20 diacid as the structural feature under study.
• Peptidase resistance. DPP-4 digestion studies in which the Aib substitutions are the variable, run against unmodified GIP and GLP-1.

What you are actually comparing between listings

• Total mass. This cartridge holds 60 mg. Research listings elsewhere are commonly 10 mg or 15 mg, so one unit here carries four to six times the peptide.
• Format. Pre-mixed solution at a stated 20 mg/ml against lyophilised powder requiring bacteriostatic water and a concentration calculation.
• Cost per milligram. At £170 for 60 mg this works out at £2.83 per mg.

For related incretin pharmacology, Retatrutide Pen 40mg adds glucagon receptor activity to the same two targets, and Cagrilintide Pen 10mg acts on the unrelated amylin and calcitonin receptor complexes.

Handling and storage

Store at 2–8 °C, keep refrigerated and protect from light. Keep the cartridge sealed until use, then upright, and observe aseptic technique. Do not freeze: acylated peptides of this size aggregate readily under freeze–thaw cycling and under prolonged agitation. Orders placed before 2pm are dispatched the same working day, cold-packed, in plain outer packaging.

References

Literature on the molecule. These describe tirzepatide as a compound and none is a claim about this product.

1. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3–14. PMID 30473097.

Research use only

This material is supplied strictly for in-vitro research and analytical purposes. It is not for human or veterinary administration and not for any diagnostic or therapeutic application. It holds no marketing authorisation and is not a licensed medicine. Confirm the current regulatory position before drafting institutional documentation, and clear the material through your own ethics, COSHH and biosafety processes before ordering.